Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, explains some of the strategies that payers can use to improve cost management and increase patient access related to chimeric antigen receptor T-cell (CAR T) therapies.
Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, explains some of the strategies that payers can use to improve cost management and increase patient access related to chimeric antigen receptor T-cell (CAR T) therapies.
Transcript
What are some strategies that payers can implement to better manage costs related to CAR T therapies and improve patient access?
That's a great question and a loaded one. I don't know the answer to that because I believe that the CAR T products and the entire pipeline has challenged both health systems and payers alike, because it is so extremely expensive—and it's not just for the cost of the product itself. It's also the before care with the leukapheresis and the lymphodepleting chemotherapy. It's the during care of the product, and then it's the aftercare, which can vary.
There are different contracts in place at this time point. There are single-case agreements as a standard. I think payers have looked at different models of outcome-based agreements and value-based agreements. Beyond single-case agreements, they've been looking at potentially a center of excellence type of model. I'm actually really looking forward to seeing how we can work together. I think it is going to be a team effort, because these products continue to come out and they're very, very expensive. It's a challenge.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Managing Skin Conditions: Highlighting Ruxolitinib Cream, Phototherapy Efficacy and Cost
April 8th 2025Research presented at the 2025 Academy of Managed Care Pharmacy annual meeting analyzed real-world treatment outcomes for dermatologic conditions, specifically highlighting the efficacy of ruxolitinib cream for atopic dermatitis and the potential for phototherapy to delay costly biologic initiation.
Read More
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More